Conclusion
Following the identification of a raised FGF23 level functional imaging was undertaken to identify the possible source of a FGF23-producing tumour. PMTs are highly vascular tumours that express somatisation receptors (subtype 2A), which can be identified via an octreotide scan (figure 1) 3 .
A MRI of the right thigh was then undertaken. This demonstrated a well-defined infiltrative enhancing lesion in the right proximal thigh within the adductor musculature (figure 2). This patient has been referred for consideration of surgical resection.
Imaging studies
A 77 year old female was referred to endocrinology with an incidental finding of hypophosphataemia (0.26 mmol/L) on routine bloods. She described a slight unsteadiness on her feet, but denied bone pain or overt muscle weakness. Past medical history included Type 2 Diabetes Mellitus, a left humeral fragility fracture and the subsequent diagnosis of osteoporosis 2 years previously.
At presentation the corrected calcium was slightly elevated (2.64 mmol/L), which normalised when repeated, with suppression of parathyroid hormone (PTH; 0.8 pmol/L) and adequate 25-hydroxyvitamin D concentrations (71 nmol/L). Renal function was normal and no paraproteins were detected. Phosphate levels were suboptimal for approximately 3 years, however, had been normal prior to this. FGF23 was found to be significantly elevated (186 RU/ ml; normal range <100). 
Case report

FGF23 & phosphate homeostasis
Tumour-induced osteomalacia is a rare paraneoplastic disorder characterised by hypophosphataemia due to decreased renal tubular reabsorption of phosphate as a result of tumour FGF23 overproduction.
The majority of tumours responsible for this condition are phosphaturic mesenchymal tumours (PMTs) of the mixed connective tissue variant 2 . These tumours are often small, slow growing, occur in diverse locations and are largely benign, however, can metastasise. Other tumours associated include osteosarcomas and advanced metastatic cancers of the colon and prostate.
